Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs BEAM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BEAM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–7 Matrix Metrics)

BEAM Overall Winner 6-Pillar Tally: CRSP 2 – 3 BEAM (1 Tie) Matrix Metrics: CRSP 7 – 3 BEAM

As of Nov 16, 2026, Beam Therapeutics Inc. (BEAM) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas BEAM carries 45.9/100 (HOLD) at $21.29 (N/M Forward P/E, -267.7% operating margin).

  • Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. BEAM 45.9/100 HOLD), BEAM captures the overall institutional head-to-head verdict (3–7 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-267.7% vs. -2058.6% operating margin) and revenue trajectory (-96.8% vs. +1325.1% YoY).
  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs BEAM
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $48.88 · SMA50: $51.80
BEAM NASDAQ Head-to-Head Winner
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$21.29
-6.75% 1D
Market Cap $2.4B
TTM Revenue $147M
Forward P/E N/M
Beta / 30D Vol 2.24β · 86% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 30.0 Fund 52.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $25.54 · SMA50: $24.99

6-Pillar Scorecard Institutional Category Breakdown (CRSP 2 – 3 BEAM)

Columns: Metric · CRSP · BEAM
1. Valuation Multiples CRSP
Forward P/E 23.4x N/M
Trailing P/E 23.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 16.8x
2. Growth & Scale CRSP
Revenue Growth (YoY) +1325.1% -96.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $25M $147M
Market Cap $4.1B $2.4B
3. Profitability & Quality BEAM
Gross Margin N/A N/A
Operating Margin -2058.6% -267.7%
Net Profit Margin 0.0% -73.9%
Return on Equity (ROE) -25.6% -11.3%
4. Balance Sheet & Cash Flow BEAM
Cash Generation (TTM) -$378M -$398M
Cash Flow Margin N/A N/A
Net Cash / Leverage $588M Net Debt (0.47x D/E) $31M Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BEAM
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 97.8% (52nd %ile) 66.0% (42nd %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 0.47x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (7) vs BEAM (3)
Institutional Metric CRSP BEAM Criterion Row Edge
Market Capitalization
Scale
$4.1B $2.4B Larger Scale CRSP
Trailing P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Forward P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+1325.1% -96.8% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-2058.6% -267.7% Higher Margin BEAM
Net Profit Margin
Profitability
0.0% -73.9% Higher Margin CRSP
Return on Equity (ROE)
Capital Efficiency
-25.6% -11.3% Higher ROE BEAM
52-Week Range Position
Momentum
1% ($40–$63) 6% ($20–$38) Stronger Trend BEAM
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol 2.24β · 86% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$25M $147M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 16.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) -$398M ($31M Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BEAM +8.25 pp
CRSP: -17.54% · BEAM: -9.29%
3M Horizon BEAM +3.46 pp
CRSP: -23.33% · BEAM: -19.87%
6M Horizon CRSP +4.22 pp
CRSP: -16.37% · BEAM: -20.59%
1Y Horizon BEAM +18.83 pp
CRSP: -20.54% · BEAM: -1.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRSP Revenue BEAM Revenue CRSP Op. Margin BEAM Op. Margin Margin Leader
FY2018 $0M N/A -5087.8% N/A CRSP
FY2019 $290M $0M 16.1% -417522.2% CRSP
FY2020 $0M $0M -49295.5% -553166.7% CRSP
FY2021 $910M $50M 40.8% -757.0% CRSP
FY2022 $0M $60M -56190.4% -555.6% BEAM
FY2023 $370M $380M -60.0% -46.7% BEAM
FY2024 $40M $60M -1250.4% -654.3% BEAM
FY2025 $0M $140M -18933.6% -274.6% BEAM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BEAM BREAKDOWN
103d in phase · OBV DISTRIBUTION
Current IV 66.0%
IV Percentile 42nd %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BEAM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4B market capitalization and -267.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs BEAM Key Questions & Quantitative Answers

As of Nov 16, 2026, Beam Therapeutics Inc. (BEAM) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas BEAM carries 45.9/100 (HOLD) at $21.29 (N/M Forward P/E, -267.7% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. BEAM 45.9/100 HOLD), BEAM captures the overall institutional head-to-head verdict (3–7 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-267.7% vs. -2058.6% operating margin) and revenue trajectory (-96.8% vs. +1325.1% YoY). Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with BEAM at -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while BEAM shifted +180.0%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BEAM.

CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus BEAM (-11.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, BEAM carries 66.0% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.